{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.983","upperLimit":"3.33","value":"1.92"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Time to reach maximum (peak) plasma concentration after dose administration (time). Actual sampling times were taken into consideration for the pharmacokinetic analysis.","dispersionType":"Full Range","groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"OG000","title":"Asciminib"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic (PK) analysis set (PAS) included all participants who provided at least one evaluable PK concentration.","reportingStatus":"POSTED","timeFrame":"Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose","title":"PK Parameter: Tmax for Asciminib","type":"SECONDARY","unitOfMeasure":"hour (hr)"}